Profile data is unavailable for this security.
About the company
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
- Revenue in USD (TTM)787.65m
- Net income in USD-366.29m
- Incorporated1991
- Employees927.00
- LocationIonis Pharmaceuticals Inc2855 Gazelle CourtCARLSBAD 92010United StatesUSA
- Phone+1 (760) 931-9200
- Fax+1 (302) 655-5049
- Websitehttps://www.ionispharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.89bn | 376.00 | -- | 11.27 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Organon & Co | 6.26bn | 1.02bn | 5.04bn | 10.00k | 4.91 | -- | 4.01 | 0.8052 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 5.07bn | 373.00 | 18.93 | 60.37 | 13.93 | 6.11 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
BridgeBio Pharma Inc | 218.60m | -538.26m | 5.21bn | 550.00 | -- | -- | -- | 23.82 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Apellis Pharmaceuticals Inc | 396.59m | -528.63m | 5.76bn | 702.00 | -- | 29.17 | -- | 14.52 | -4.48 | -4.48 | 3.34 | 1.63 | 0.5121 | 0.5042 | 3.70 | 564,944.40 | -68.26 | -73.88 | -93.25 | -90.03 | 85.25 | -- | -133.29 | -326.49 | 2.50 | -59.78 | 0.6775 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
Ionis Pharmaceuticals Inc | 787.65m | -366.29m | 6.12bn | 927.00 | -- | 15.67 | -- | 7.77 | -2.56 | -2.56 | 5.50 | 2.68 | 0.2852 | 0.362 | 12.77 | 849,673.10 | -13.26 | -6.30 | -15.38 | -7.44 | 98.84 | 98.75 | -46.50 | -21.23 | 5.83 | -- | 0.7671 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Immunitybio Inc | 622.00k | -583.20m | 6.17bn | 628.00 | -- | -- | -- | 9,914.25 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Exelixis Inc | 1.85bn | 205.05m | 6.38bn | 1.31k | 33.87 | 3.04 | 27.70 | 3.45 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Elanco Animal Health Inc | 4.42bn | -1.23bn | 6.69bn | 9.30k | -- | 1.07 | -- | 1.51 | -2.50 | -2.50 | 8.96 | 12.63 | 0.2959 | 1.18 | 5.39 | 474,946.30 | -8.25 | -3.27 | -9.15 | -3.65 | 56.28 | 54.28 | -27.87 | -11.53 | 1.35 | 1.18 | 0.4813 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Blueprint Medicines Corp | 282.21m | -288.29m | 6.73bn | 645.00 | -- | 21.60 | -- | 23.86 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Cytokinetics, Inc. | 7.53m | -526.24m | 6.83bn | 423.00 | -- | -- | -- | 906.47 | -5.45 | -5.45 | 0.078 | -3.80 | 0.0082 | -- | 10.53 | 17,801.42 | -57.23 | -43.14 | -63.72 | -47.22 | -- | -- | -6,988.63 | -540.47 | -- | -16.52 | 2.66 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Revolution Medicines Inc | 11.58m | -436.37m | 6.85bn | 378.00 | -- | 3.62 | -- | 591.87 | -3.77 | -3.77 | 0.1024 | 11.09 | 0.0081 | -- | 3.91 | 30,634.92 | -30.37 | -29.76 | -32.71 | -32.59 | -- | -- | -3,768.28 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.93bn | 2.80k | 22.70 | 1.88 | 7.08 | 1.80 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Vaxcyte Inc | 0.00 | -402.27m | 7.17bn | 254.00 | -- | 5.07 | -- | -- | -4.07 | -4.07 | 0.00 | 13.01 | 0.00 | -- | -- | 0.00 | -33.33 | -34.22 | -36.11 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
Intra-Cellular Therapies Inc | 464.37m | -139.67m | 7.26bn | 610.00 | -- | 11.21 | -- | 15.64 | -1.46 | -1.46 | 4.84 | 6.14 | 0.6262 | 1.90 | 4.91 | 761,262.30 | -18.84 | -38.27 | -21.89 | -42.77 | 92.73 | -- | -30.08 | -128.42 | 5.31 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 21.52m | 14.77% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 14.00m | 9.61% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 13.20m | 9.06% |
Bellevue Asset Management AGas of 31 Dec 2023 | 8.71m | 5.98% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 7.27m | 4.99% |
ClearBridge Investments LLCas of 31 Dec 2023 | 4.71m | 3.23% |
Wellington Management Co. LLPas of 31 Dec 2023 | 4.62m | 3.17% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 4.10m | 2.82% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.01m | 2.75% |
Pictet Asset Management SAas of 31 Dec 2023 | 3.52m | 2.41% |